Cybin Inc. Common Stock (HELP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cybin Inc. Common Stock (HELP) has a cash flow conversion efficiency ratio of -0.117x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.84 Million) by net assets ($375.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cybin Inc. Common Stock net asset quality index to measure how much of total assets are equity-financed.
Cybin Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Cybin Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check HELP total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Cybin Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cybin Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Senao International Co Ltd
TW:2450
|
0.135x |
|
TIDEWATER RENEWABLES LTD
F:7GZ
|
-0.003x |
|
Dynamic Cables Limited
NSE:DYCL
|
0.011x |
|
Kaldalón hf.
IC:KALD
|
N/A |
|
ODFJELL TECHNOLOGYLTD
F:ND4
|
0.302x |
|
Veranda Learning Solutions Limited
NSE:VERANDA
|
-0.045x |
|
Eaton Vance California MBF
NYSE MKT:EVM
|
0.036x |
|
Trimegah Securities Tbk
JK:TRIM
|
-0.199x |
Annual Cash Flow Conversion Efficiency for Cybin Inc. Common Stock (2017–2025)
The table below shows the annual cash flow conversion efficiency of Cybin Inc. Common Stock from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Cybin Inc. Common Stock (HELP) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $237.20 Million | $-101.30 Million | -0.427x | -80.93% |
| 2024-03-31 | $291.93 Million | $-68.91 Million | -0.236x | +76.00% |
| 2023-03-31 | $48.23 Million | $-47.43 Million | -0.983x | -65.65% |
| 2022-03-31 | $76.16 Million | $-45.21 Million | -0.594x | -168.68% |
| 2021-03-31 | $86.12 Million | $-19.03 Million | -0.221x | -23002.44% |
| 2020-03-31 | $1.45 Million | $-1.38K | -0.001x | +99.55% |
| 2019-03-31 | $394.73K | $-83.78K | -0.212x | +60.57% |
| 2018-03-31 | $440.25K | $-237.03K | -0.538x | -5701.70% |
| 2017-03-31 | $292.78K | $2.81K | 0.010x | -- |
About Cybin Inc. Common Stock
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical tr… Read more